Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06045195 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Study acronym: Pembro-FLASH
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 2026 to Jan 2027
    • Start date: Jan 2025 to Aug 2025
    • Study completion date: Jan 2028 to Jan 2029
    • Study arms: 0 to 1
    v3
  2. Primary completion date: Jan 2025 to Jan 2026
    • Start date: Jan 2024 to Jan 2025
    • Study completion date: Jan 2027 to Jan 2028
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care
Trial Details
NCT Number NCT06045195
Lead Sponsor University of Cologne
Conditions
(from sponsor)		 Hodgkin Lymphoma
Related terms Hodgkin Disease
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov